Tokyo - Delayed Quote JPY

Pharma Foods International Co., Ltd. (2929.T)

940.00
-8.00
(-0.84%)
At close: 3:30:00 PM GMT+9
Loading Chart for 2929.T
  • Previous Close 948.00
  • Open 935.00
  • Bid --
  • Ask --
  • Day's Range 931.00 - 941.00
  • 52 Week Range 722.00 - 1,254.00
  • Volume 48,900
  • Avg. Volume 131,420
  • Market Cap (intraday) 27.315B
  • Beta (5Y Monthly) 1.53
  • PE Ratio (TTM) 9.99
  • EPS (TTM) 94.14
  • Earnings Date Jun 10, 2025
  • Forward Dividend & Yield 25.00 (2.64%)
  • Ex-Dividend Date Jul 30, 2025
  • 1y Target Est --

Pharma Foods International Co., Ltd. engages in the development and sale of functional food ingredients in Japan. It also focuses on biomedical drug discovery of antibody, and peptide and diagnostics. Pharma Foods International Co., Ltd. was founded in 1997 and is based in Kyoto, Japan.

www.pharmafoods.co.jp

642

Full Time Employees

July 31

Fiscal Year Ends

Recent News: 2929.T

View More

Performance Overview: 2929.T

Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

2929.T
4.71%
Nikkei 225 (^N225)
5.36%

1-Year Return

2929.T
10.63%
Nikkei 225 (^N225)
1.64%

3-Year Return

2929.T
42.40%
Nikkei 225 (^N225)
42.86%

5-Year Return

2929.T
17.90%
Nikkei 225 (^N225)
88.42%

Compare To: 2929.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 2929.T

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    27.55B

  • Enterprise Value

    28.89B

  • Trailing P/E

    10.08

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.46

  • Price/Book (mrq)

    2.29

  • Enterprise Value/Revenue

    0.48

  • Enterprise Value/EBITDA

    5.59

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.42%

  • Return on Assets (ttm)

    7.50%

  • Return on Equity (ttm)

    25.09%

  • Revenue (ttm)

    60.35B

  • Net Income Avi to Common (ttm)

    2.67B

  • Diluted EPS (ttm)

    94.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.11B

  • Total Debt/Equity (mrq)

    103.29%

  • Levered Free Cash Flow (ttm)

    1.65B

Research Analysis: 2929.T

View More

Company Insights: 2929.T

Research Reports: 2929.T

View More

People Also Watch